Maaly Abdel Halim Abdel Fattah1,2,3*, Fatima Babiker Ali Babiker3 and Selwa Abdulla Alhazzaa2,3
1Ophthalmology Department, Cairo University, College of medicine, Cairo, Egypt
2Ophthalmology Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3Al-Faisal University college of Medicine, Riyadh, Saudi Arabia
*Corresponding Author: Maaly Abdel Halim Abdel Fattah, Ophthalmology Department, Cairo University, College of medicine, Cairo, Egypt and Ophthalmology Department, King Faisal Specialist Hospital and Research Center and Al-Faisal University college of Medicine, Riyadh, Saudi Arabia.
Received: February 02, 2020; Published: February 24, 2020
Sunitinib and Ponatinib are two biological drugs that have greatly contributed to the treatment advances of different types of cancer. However, the ocular adverse effects of those drugs were not well studied and only a few case reports, within the literature, described patients who developed vision loss and ocular changes. In this study, we reported the clinical presentation of the first two Saudi patients presenting with a sudden loss of vision due to recent lines of treatment. The effect of these drugs has strongly implied the importance of cautious use and the need for further studies on their ocular side effects.
Keywords:Blindness; Ocular; Biological; Sunitinib; Ponatinib and Anticancer
Citation: Maaly Abdel Halim Abdel Fattah., et al. “Sudden Iatrogenic Blindness in Patients Treated with Biological Cancer Therapy”. Acta Scientific Ophthalmology 3.3 (2020): 13-15.
Copyright: © 2020 Maaly Abdel Halim Abdel Fattah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.